Tempus AI also announced a promising new partnership with AstraZeneca and Pathos AI to aid cancer research and treatment. Tempus AI could have an incredible runway for growth, but its valuation ...

Tempus AI shares were 14% higher, at $49.35, after the company said it has entered into multi-year strategic collaborations with AstraZeneca and Pathos AI. The technology company said the ...

Shares of Tempus AI (NASDAQ: TEM) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain came after the healthcare artificial intelligence (AI) company announced a multiyear ...

In the last three months, 9 analysts have published ratings on Tempus AI TEM, offering a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their recent ...

Tempus AI announced a collaboration with AstraZeneca and Pathos AI. The deal will generate $200 million for Tempus AI in data licensing and model development fees. Tempus AI has invested heavily ...